What is the current stock price of NKGen Biotech, Inc. Common Stock (NKGN)?

As of the latest market data, NKGen Biotech, Inc. Common Stock (NKGN) is trading at $0.06. The stock has seen a loss of 0.00% today.

Does NKGen Biotech, Inc. Common Stock (NKGN) pay a dividend?

Based on current data, NKGen Biotech, Inc. Common Stock does not have a confirmed active dividend policy.

What is the market cap of NKGen Biotech, Inc. Common Stock?

The current market capitalization of NKGen Biotech, Inc. Common Stock (NKGN) is approximately unavailable.

NKGN

NKGen Biotech, Inc. Common Stock·Healthcare

0.06

0.000%(+0.00)

Market Open

Last Updated: — ET

52W L: $0.0052W H: $0.77

NKGN NEWS

globenewswire.com

May 19

NKGen Biotech Expands Clinical Trial Site Network for Alzheimer's Disease Program Across U.S. to Improve Patient Access and Support Enrollment

New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer's disease.

globenewswire.com

Apr 9

NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit

SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present data on its lead investigational program, troculeucel, at the 8th Annual Neuroimmunology Drug Development Summit being held April 14-16, 2026, in Boston, Massachusetts.

globenewswire.com

Mar 23

NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™

Pooled analyses in patients with moderate Alzheimer's show dose-related cognitive benefit and signs of durability. 100% of patients remained stable or improved, with 50% improving from moderate to mild cognitive function.

globenewswire.com

Mar 10

NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026

SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced upcoming oral and poster presentations at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (“AD/PD™ 2026”), taking place March 17-21, 2026, in Copenhagen, Denmark and virtually.

Company Profile

NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed Phase 1 trial and a HER2-CAR NK cell therapy candidate in pre-clinical trial to treat refractory solid tumors. It has a strategic partnership with HekaBio K.K., a Japan-based healthcare platform, to develop, conduct clinical trials, obtain regulatory approvals, manufacture, and commercialize the company's autologous NK cell therapy product candidates for central nervous system and autoimmune conditions in Japan. The company also has a license agreement with NKMAX Co., Ltd. for the research and development of its NK cell program. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2023-10-02

Beta

0.65

Websitenkgenbiotech.com↗